We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04985721
Recruitment Status : Recruiting
First Posted : August 2, 2021
Last Update Posted : March 4, 2022
Sponsor:
Information provided by (Responsible Party):
Peter MacCallum Cancer Centre, Australia

Tracking Information
First Submitted Date  ICMJE June 28, 2021
First Posted Date  ICMJE August 2, 2021
Last Update Posted Date March 4, 2022
Actual Study Start Date  ICMJE February 24, 2022
Estimated Primary Completion Date August 1, 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 29, 2021)
Evaluation of clinical benefit rate (CBR) in patients with advanced tumours harbouring molecular profiles consistent with homologous recombination defeciency (HRD), without a known pathogenic germline BRCA1 or BRCA2 mutation. [ Time Frame: 12 weeks after commencement of treatment ]
CBR, defined as the proportion of patients with either objective response (partial response (PR) + complete response (CR)) as best response, or stable disease (SD) at 12 weeks post registration, as determined by the Investigator by RECIST 1.1 in cohort A
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 29, 2021)
  • Efficacy of pamiparib in combination with tislelizumab in patients with advanced tumours harbouring molecular profiles consistent with HRD, and without a known pathogenic germline BRCA1 or BRCA2 mutation [ Time Frame: At the end of the study, approximately 4 years after the first participant commences treatment ]
    Efficacy will be measured by:
    • overall response rate (ORR) - defined as the proportion of patients with an objective response (partial response + complete response) as best response (as determined by the Investigator by RECIST 1.1)
  • Efficacy of pamiparib in combination with tislelizumab in patients with advanced tumours harbouring molecular profiles consistent with HRD, and without a known pathogenic germline BRCA1 or BRCA2 mutation [ Time Frame: At the end of the study, approximately 4 years after the first participant commences treatment ]
    Efficacy will be measured by: -progression free survival (PFS) - defined as the time from first dose of study medication to the first occurrence of disease progression, as determined by the Investigator according to RECIST 1.1, or death from any cause, whichever occurs first
  • Efficacy of pamiparib in combination with tislelizumab in patients with advanced tumours harbouring molecular profiles consistent with HRD, and without a known pathogenic germline BRCA1 or BRCA2 mutation [ Time Frame: At the end of the study, approximately 4 years after the first participant commences treatment ]
    Efficacy will be measured by: -overall survival (OS) - defined as the time from first dose of study medication to death from any cause
  • Evaluation of CBR of pamiparib in combination with tislelizumab in patients with advanced tumours harbouring molecular profiles consistent with HRD (independent of germline BRCA1 or BRCA2 mutation status) [ Time Frame: 12 weeks post commencement of treatment ]
    CBR, defined as the proportion of patients with either objective response (partial response (PR) + complete response (CR)) as best response, or stable disease (SD) at 12 weeks post registration, as determined by the Investigator by RECIST 1.1 in cohort A and B
  • Severity of Treatment -Emergent Events (Safety of pamiparib in combination with tiselizumab) [ Time Frame: At the end of the study, approximately 4 years after the first participant commences treatment ]
    Severity of adverse events as determined by NCI CTCAE 5.0
  • Determination of HRD phenotype as a predictor of response [ Time Frame: At the end of the study, approximately 4 years after the first participant commences treatment ]
    A tumour based whole genome HRD assay will provide a binary outcome as to whether HRD is "present" or "absent". Logistic regression models will be used to compare CBR between patients with tumours that have HRD "present" vs "absent".
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects
Official Title  ICMJE An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects
Brief Summary This study will describe the efficacy of pamiparib in combination with tislelizumab in patients with advanced tumours harbouring molecular profiles consistent with homologous recombination deficiency (HRD), agnostic of tumour origin. A tumour-agnostic approach has been adopted in this study due to the broad activity of PARP inhibitors across multiple tumour types. In addition, response to PARP inhibitors has been demonstrated in patients with genomic features associated with HRD, even in the absence of germline BRCA1 or BRCA2 mutations. These results suggest that the presence of HRD itself is the key predictive biomarker for PARP inhibitor efficacy. This paves the way for a precision-oncology, tumour-agnostic approach to patient selection for treatment, rather than the traditional tumour site-of-origin basis for which the current PARP inhibitor approvals exist. To investigate this, cohort A of this study includes patients with genomic features of HRD, but without a germline BRCA1 or BRCA2 mutation. Demonstration of clinical efficacy in this cohort will provide strong support to the tumour-agnostic, precision-oncology approach for patient selection for PARP inhibitor or PARP inhibitor combination treatment. This forms the primary objective of the study. The study will consist of two cohorts, broadly, cohort A - patients without a pathogenic BRCA1 or BRCA2 mutation but with other germline or somatic mutations in other HRD genes; cohort B- patients with a pathogenic BRCA1 or BRCA2
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Cancer
Intervention  ICMJE
  • Drug: Pamiparib
    40 mg orally twice a day
  • Drug: Tislelizumab
    200 mg IV every 21 days
Study Arms  ICMJE Experimental: Pamiparib and Tiselizumab
Interventions:
  • Drug: Pamiparib
  • Drug: Tislelizumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 29, 2021)
60
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 1, 2025
Estimated Primary Completion Date August 1, 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Have provided written informed consent
  2. Male or female ≥ 18 years of age
  3. Patient has documentation of at least 1 of the following genomic features associated with HRD

    • Cohort A - any of:

      • A germline or somatic genetic alteration that is known or suspected to be deleterious in one of the following HR-related genes (ATM, CDK12, PALB2, ARID1A, ATRX, BLM, BARD1, BRIP1, CHEK1, CHEK2, FANCA, FANCF, FANCG, FANCI, FANCL, FANCM, MSH2, NBN, RAD50, RAD51C, RAD51D, WRN)
      • A somatic genetic alteration that is known or suspected to be deleterious in BRCA1 or BRCA2
      • A prevalent mutational signature 3 as determined by WGS (≥ 20% of total mutations attributed)
      • The presence of a positive HRD status using a NGS assay that includes assessment for genomic instability
      • Cohort A excludes high grade serous ovarian cancer, TNBC, and prostate cancer
    • Cohort B - a pathogenic germline BRCA1 or BRCA2 mutation Note: Genomic features associated with HRD must have been determined from a sample obtained ≤ 12 months before the date of registration into this study with the exception of germline genetic alterations which can have been determined from a sample obtained at any time.
  4. Patient agrees to the collection and use of their fresh tumour biopsy sample during screening for WGS Note: A fresh tumour biopsy not required for patients who have had WGS performed within 12 months prior to registration to the study
  5. Continues to meet all the inclusion criteria as per the TRIAGE Framework protocol
  6. Measurable disease, as defined by RECIST 1.1 (see Appendix 2)
  7. Adequate haematological and end-organ function, defined by the following laboratory results obtained within 7 days prior to registration, independent of blood or platelet transfusion within 2 weeks:

    • Haemoglobin ≥ 90 g/L
    • ANC ≥ 1.5x109/L
    • Platelet count ≥ 100 x109/L
    • ALT ≤ 3.0 x the ULN, irrespective of the presence or absence of liver metastases
    • AST ≤ 3.0 x the ULN, irrespective of the presence or absence of liver metastases
    • Serum bilirubin ≤ 1.5 x ULN (On fractionation ≤ 90% of total bilirubin should be unconjugated.

    Total bilirubin must be <4 x ULN for patients with Gilbert's Syndrome)

    • Serum creatinine ≤ 1.5x ULN or eGFR ≥ 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (appendix 5)
    • INR ≤ 1.5x ULN (≤2.5x ULN if on anticoagulants)
  8. Patient has the ability to take oral medications without medical history of malabsorption or other chronic gastrointestinal disease, or other conditions that may harm compliance and/or absorption of the study treatment
  9. WOCBP must agree to use a highly effective method of birth control for the duration of the study and for 6 months after the last dose of study treatment (see Appendix 3), and have a negative serum pregnancy test within 7 days of study registration
  10. Non-sterile males and their female partners must agree to use a highly effective method of birth control for the duration of the study and for 6 months after the last dose of study treatment. Non- sterile males must avoid sperm donation for the duration of the study and for at least 6 months after the last study drug
  11. Female patient must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration
  12. Patient is willing and able to comply with the protocol for the duration of the study including undergoing biopsies, treatment, and scheduled visits and examination including follow up

Exclusion Criteria:

  1. One or more of the exclusion criteria as per the TRIAGE Framework protocol applies
  2. Any previous treatment with a PARP inhibitor

    Note: Prior immune checkpoint blockade is permitted provided all the criteria below are met:

    • Patients must not have received the immune checkpoint blockade within 28 days of study registration
    • Patients must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy
    • All AEs while receiving prior immunotherapy must have completely resolved or resolved to grade

      1 prior to screening for this study. Patients with an endocrine AE due to immunotherapy are permitted provided they are stably maintained on appropriate replacement therapy and are asymptomatic

    • Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not require maintenance doses of > 10 mg prednisolone or equivalent per day
  3. Any unresolved toxicity (≥CTCAE grade 2) from previous anti-cancer therapy, with the exception of alopecia Note: Patients with irreversible toxicity that is not reasonably expected to be exacerbated by the study treatment (e.g. hearing loss, peripheral neuropathy) are eligible
  4. Treatment with strong CYP3A inducers within 10 days (or ≤ 5 half-lives, whichever is shorter) prior to registration. Known need for treatment with strong CYP3A4 inducers during study treatment.
  5. Symptomatic or current history of actively progressing CNS metastases. Patients with a history of treated CNS lesions are eligible, provided that all of the following criteria are met:

    • Measurable disease per RECIST 1.1 must be present outside the CNS
    • In patients who have received CNS-directed therapy, there is no clinical evidence of interim progression between completion of CNS-directed therapy and registration to the study (radiological re-assessment is not required)
    • The patient has not received radiotherapy within 14 days prior to registration Note: Anticonvulsant therapy at a stable dose is permitted

    Note: Patients with asymptomatic brain metastases in which CNS-directed therapy is not indicated are eligible

  6. History of leptomeningeal disease
  7. Mean QTc ≥ 470 ms calculated from triplicate ECGs using Fredericia's Correction
  8. Active autoimmune disease or history of autoimmune disease that may relapse, with the following exceptions:

    • Controlled type 1 diabetes
    • Hypothyroidism managed with no treatment other than with hormone replacement therapy
    • Controlled celiac disease
    • Skin disease not requiring systemic treatment (e.g. vitiligo, psoriasis, alopecia)
    • Any other disease that is not expected to recur in the absence of external triggering factors
  9. Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 2 weeks prior to registration, with the following exceptions:

    • Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent)
    • Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with minimal systemic absorption
    • Short course (≤ 7 days) of corticosteroid prescribed prophylactically or for the treatment of a non- autoimmune condition
  10. Positive HIV test at screening
  11. Patients with active HBV (chronic or acute; defined as having a positive HBsAg test at screening) or HCV Note: Patients with a past or resolved HBV infection (defined as the presence of HBcAb and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA
  12. Patients with severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy, including active tuberculosis and COVID-19
  13. Patients with a history of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung diseases, etc.
  14. History of non-viral hepatitis or cirrhosis
  15. Any of the following cardiovascular criteria:

    • Current evidence of cardiac ischemia.
    • Current symptomatic pulmonary embolism.
    • Acute myocardial infarction ≤ 6 months prior to study registration.
    • Heart failure of New York Heart Association Classification III or IV (See Appendix 6) ≤ 6 months prior to study registration.
    • Grade ≥ 2 ventricular arrhythmia ≤ 6 months prior to study registration.
    • History of cerebrovascular accident within 6 months before first dose of study drugs.
  16. Has been administered a live vaccine within 4 weeks prior to registration
  17. Known sensitivity to any component of pamiparib and/or tislelizumab
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Stephen Luen, MBBS +61 3 8559 5000 stephen.luen@petermac.org
Contact: Jayesh Desai, MBBS +61 8559 8339 jayesh.desai@petermac.org
Listed Location Countries  ICMJE Australia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04985721
Other Study ID Numbers  ICMJE 20/044
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Peter MacCallum Cancer Centre, Australia
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Peter MacCallum Cancer Centre, Australia
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Stephen Luen, MBBS Peter MacCallum Cancer Institute
PRS Account Peter MacCallum Cancer Centre, Australia
Verification Date August 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP